Bon Natural Life's interim results reflect 1-for-25 share consolidation and offering

The interim results

Bon Natural Life Limited (Nasdaq: BON) furnished unaudited condensed consolidated statements for the six months ended March 31, 2025 on Form 6-K dated September 29, 2025. Revenue for the period was $7,949,845, down from $10,183,553 a year earlier. Gross profit fell to $1,907,848 from $2,968,437. Income from operations rose to $284,050 from $84,505, because operating expenses fell, with research and development costs dropping to $96,472 from $890,384.

The company reported net income attributable to its shareholders of $169,227, against a loss of $10,519 a year earlier. Basic earnings per share were $0.56, against a loss of $0.20, and diluted earnings per share were $0.50. The share counts are restated for a 1-for-25 consolidation approved by shareholders at an extraordinary general meeting on April 15, 2025 and effective May 19, 2025.

The profit is thin and came with a cash drain from operations. The statements show net cash used in operating activities of $4,295,567 for the six months, against $1,884,173 a year earlier, and the line for the long-term other receivable alone absorbed $14,500,947. The profit also comes against a currency loss. The foreign currency translation adjustment for the six months was a loss of $1,419,950, which turned total comprehensive income into a loss of $1,284,039.

The offering and the cash

The equity statement records the issue of 3,590,528 Class A ordinary shares for a public offering, with net proceeds of $10,543,805. The cash flow statement shows the same $10,543,805 as net proceeds from issuance of ordinary shares. The offering is the main reason cash rose, from $80,466 at September 30, 2024 to $8,894,053 at March 31, 2025.

Borrowing also funded the period. The company received $7,232,644 from short-term loans and repaid $5,276,345. Short-term loans stood at $7,586,798 at March 31, 2025, up from $5,719,493 at September 30, 2024.

The equity statement also records the issue of 2,041,839 Class B ordinary shares, with a reduction of 81,674 Class A shares. The statements do not explain that movement. The company now reports both Class A and Class B ordinary shares outstanding, with 3,675,677 Class A and 2,041,839 Class B shares at March 31, 2025.

Total shareholders' equity rose to $53,905,305 from $44,349,539. Total assets were $71,584,129 at March 31, 2025, against $61,765,432 six months earlier. Total liabilities were $17,678,824, against $17,415,893. The balance sheet also shows a long-term other receivable of $14,449,247, which was nil at September 30, 2024. The statements do not say what the receivable is or when it is due.

What the statements leave open

The filing does not explain the long-term receivable, the Class B issue or the reduction in Class A shares. It also does not name the underwriters or any counsel for the offering, and it gives no offering price per share in the statements. The 6-K does not state whether the company expects further offerings or borrowings to cover its operations.

The balance sheet also shows no assets held for sale at March 31, 2025, where it carried assets and liabilities held for sale tied to the sale of the Gansu subsidiary six months earlier.

The company's annual report on Form 20-F describes a Cayman Islands holding company that operates through Hong Kong and Chinese subsidiaries. It says the company does not expect to pay cash dividends, and that its Chinese subsidiaries must set aside 10% of after-tax profits each year, if any, into statutory reserves until those reserves reach half of registered capital. The reserves are not distributable as cash dividends.

Report an error

Companies in this story

BONBon Natural Life LimitedNASDAQ · ChinaOpen the starter desk